A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pheast Therapeutics
National Institutes of Health Clinical Center (CC)
Artios Pharma Ltd
OHSU Knight Cancer Institute
Incyte Corporation
Merck Sharp & Dohme LLC
Incyte Corporation
Toray Industries, Inc
NGM Biopharmaceuticals, Inc
National Cancer Institute (NCI)
Esperas Pharma Inc.
Cyteir Therapeutics, Inc.
Eli Lilly and Company
Northwestern University
AstraZeneca
University of Maryland, Baltimore
Masonic Cancer Center, University of Minnesota
Altor BioScience
Dartmouth-Hitchcock Medical Center